Eric Hsu
2023
In 2023, Eric Hsu earned a total compensation of $260.5K as Senior Vice President, Preclinical Research & Development at InMed Pharmaceuticals, a 8% decrease compared to previous year.
Compensation breakdown
| Bonus | $38,000 |
|---|---|
| Option Awards | $5,500 |
| Salary | $217,000 |
| Total | $260,500 |
Hsu received $217K in salary, accounting for 83% of the total pay in 2023.
Hsu also received $38K in bonus and $5.5K in option awards.
Rankings
In 2023, Eric Hsu's compensation ranked 2,484th out of 2,770 executives tracked by ExecPay. In other words, Hsu earned more than 10.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,484 out of 2,770 | 10th |
Division Manufacturing | 1,375 out of 1,516 | 9th |
Major group Chemicals And Allied Products | 796 out of 855 | 7th |
Industry group Drugs | 774 out of 821 | 6th |
Industry Pharmaceutical Preparations | 552 out of 590 | 6th |
Source: SEC filing on October 28, 2024.
Hsu's colleagues
We found four more compensation records of executives who worked with Eric Hsu at InMed Pharmaceuticals in 2023.
2023
Eric Adams
InMed Pharmaceuticals
Chief Executive Officer
2023
Michael Woudenberg
InMed Pharmaceuticals
Chief Operating Officer
2023
Alexandra Mancini
InMed Pharmaceuticals
Senior Vice President, Clinical & Regulatory Affairs
2023
Jonathan Tegge
InMed Pharmaceuticals
Chief Financial Officer
News
InMed Pharmaceuticals CEO Eric Adams' 2024 pay rises 13% to $415K
October 28, 2024
InMed Pharmaceuticals CEO Eric Adams' 2023 pay falls 22% to $368K
October 27, 2023
InMed Pharmaceuticals CEO Eric Adams' 2022 pay falls 36% to $468K
October 28, 2022
InMed Pharmaceuticals CEO Eric Adams' 2021 pay jumps 73% to $735K
October 28, 2021